A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infectionRichard Elion, Javier Szwarcberg, Jean‐Michel Molina et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2013Cited by 41
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitorsTommaso Clemente, Antonella Castagna, Laura Galli et al.|BMJ Open|2024Cited by 21
Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection: Real Life Interim Analysis of an Italian Multicentre Compassionate Use ProgramElisabetta Teti, Massimo Andreoni, C Mussini et al.|Journal of Hepatology|2016Cited by 7
Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO RegistryTommaso Clemente, Vincenzo Spagnuolo, Sara Diotallevi et al.|International Journal of Antimicrobial Agents|2024Cited by 3